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Abstract
Background: Intravesical Bacillus Calmette-Guerin (BCG) is an effective treatment for bladder superficial carcinoma
and it is being tested in interstitial cystitis patients, but its precise mechanism of action remains poorly understood. It is
not clear whether BCG induces the release of a unique set of cytokines apart from its pro-inflammatory effects.
Therefore, we quantified bladder inflammatory responses and alterations in urinary cytokine protein induced by
intravesical BCG and compared the results to non-specific pro-inflammatory stimuli (LPS and TNF-α). We went further
to determine whether BCG treatment alters cytokine gene expression in the urinary bladder.
Methods: C57BL/6 female mice received four weekly instillations of BCG, LPS, or TNF-α. Morphometric analyses were
conducted in bladders isolated from all groups and urine was collected for multiplex analysis of 18 cytokines. In addition,
chromatin immune precipitation combined with real-time polymerase chain reaction assay (CHIP/Q-PCR) was used to
test whether intravesical BCG would alter bladder cytokine gene expression.
Results: Acute BCG instillation induced edema which was progressively replaced by an inflammatory infiltrate,
composed primarily of neutrophils, in response to weekly administrations. Our morphological analysis suggests that
these polymorphonuclear neutrophils are of prime importance for the bladder responses to BCG. Overall, the
inflammation induced by BCG was higher than LPS or TNF-α treatment but the major difference observed was the
unique granuloma formation in response to BCG. Among the cytokines measured, this study highlighted the importance
of IL-1β, IL-2, IL-3, IL-4, IL-6, IL-10, IL-17, GM-CSF, KC, and Rantes as discriminators between generalized inflammation
and BCG-specific inflammatory responses. CHIP/Q-PCR indicates that acute BCG instillation induced an up-regulation
of IL-17A, IL-17B, and IL-17RA, whereas chronic BCG induced IL-17B, IL-17RA, and IL-17RB.
Conclusion: To the best of our knowledge, the present work is the first to report that BCG induces an increase in the
IL-17 family genes. In addition, BCG induces a unique type of persisting bladder inflammation different from TNF-α, LPS,
and, most likely, other classical pro-inflammatory stimuli.
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Intravesical Bacillus Calmette-Guerin (BCG) has been
presented as a promising option for treatment of intersti-
tial cystitis [1]. However, intravesical BCG is best known
as the most effective agent for the treatment of high-grade
superficial bladder cancer [2-4]. In this context, BCG is
used to reduce both the recurrence rate of bladder tumor
and to diminish the risk of its progression [2,3]. As an
adjunct to transurethral resection, BCG is the treatment of
choice for urothelial carcinoma in-situ (CIS) and is com-
monly used for recurrent or multi-focal Ta and high grade
T1 bladder lesions [5,6].
It is not clear how BCG alters the course of cystitis or can-
cer progression. Recently, however, the susceptibility to
BCG was correlated with polymorphisms of the human
NRAMP1 gene [7], providing interesting insights into the
complexity of the genomics of BCG immunotherapy [8].
One theory is that intravesical BCG corrects an aberrant
immune imbalance in the bladder, leading to long-term
symptomatic improvement [1].
Here, we explore the possibility that BCG causes an exten-
sive local inflammatory reaction in the bladder wall [9].
Of this, the massive appearance of cytokines in the urine
of BCG-treated patients stands out [9]. Activated lym-
phocytes and macrophages are the most likely sources of
these cytokines, but at present, other cellular sources such
as urothelial cells cannot be ruled out [9]. BCG is internal-
ized and processed by neutrophils [10], professional anti-
BCG uptake by bladder urothelial cells. Representative photomicrographs indicating uptake of acid fast bacteria by the urothe-lial cells and infiltr tion of PMNsFigure 1
BCG uptake by bladder urothelial cells. Representative photomicrographs indicating uptake of acid fast bacte-
ria by the urothelial cells and infiltration of PMNs. Twenty four hours after bladder instillation with BCG, bladders were 
removed and stained with fast acid (A-C) or H&E (D-F). Acid fast-positive bacteria were detected within umbrella cells and 
underlying urothelial cells, indicating that BCG is taken up by an apparent intact epithelium (Figure 1A-C). Black wavy lines indi-
cate areas containing fast acid-positive bacteria; black arrows indicate PMNs, and red arrow indicates lymphocytes.Page 2 of 18
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in altered gene expression and secretion of particular
cytokines [9]. It was suggested that the effectiveness of
BCG treatment is determined by two processes: an inflam-
matory one, followed by a delayed type of hypersensitivity
response [11]. Others proposed three distinct phases in
the immune response to BCG. In phase 1, BCG adheres to
the urothelium via interaction between the bacterial anti-
gen 85 complex and fibronectin [6,12] and urothelial
cells. In addition to fibronectin, it has been suggested that
toll-like receptors (TLRs) -2 and -4, present in immune
cells, mediate BCG-induced immune responses [13-15].
Once internalized, BCG is processed both by professional
antigen-presenting cells and urothelial cells, resulting in
an altered gene expression [9]. This phase corresponds to
the early release of so-called inflammatory cytokines (IL-
1, IL-6, and IL-8 in humans) which may be responsible for
certain adverse effects. Phase 2 consists of recognition of
bacterial antigens by CD4 lymphocytes, which release
mainly IL-2 and IFN-γ (TH1 response). This cell activation
leads to phase 3, which consists of amplification of cyto-
toxic-populations: CD8 T cells, gamma-delta lym-
phocytes, macrophages, and natural killer (NK) cells. All
these cells also release cytokines which then regulate BCG
response [16].
More recently, studies have shown that mycobacterial
DNA contains high amounts of CpG motifs. These CpG
motifs induce tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) expression [17] and increase
serum levels of mouse keratinocyte-derived chemokine
(KC), a functional homolog of human interleukin IL-8
[18]. Urinary TRAIL levels were initially undetectable in
BCG therapy patients, but levels increased after subse-
quent treatments. More importantly, patients that
responded to BCG therapy had significantly higher urine
TRAIL levels, which killed bladder tumor cells in vitro ver-
sus non-responders. Given these data, it was proposed
that TRAIL also plays a role in BCG-induced anti-tumor
effects [17].
Nevertheless, BCG's mechanism of action remains poorly
understood. Although systemic reactions have been
reported, a likely scenario is that exposure to BCG results
Time-course of bladder morphological alterations in response to weekly instillations with BCGF gure 2
Time-course of bladder morphological alterations in response to weekly instillations with BCG. Representative 
photomicrographs of a time-dependent alteration of the mouse bladder secondary to intravesical instillation of BCG. Note, the 
intense edema observed days 1–7 after the first instillation with BCG (A and B) and the subsequent invasion of inflammatory 
cells into the submucosa at day 7 (B) and a time-dependent invasion of the detrusor muscle at days 21 (C) and 28 (D-F). Gran-
uloma-like formation is indicated by wavy white lines.
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DAY 28 DAY 28 DAY 28Page 3 of 18
(page number not for citation purposes)
BMC Immunology 2007, 8:6 http://www.biomedcentral.com/1471-2172/8/6in a local immune response and massive inflammation
[6], which makes it difficult to analyze the direct effects of
BCG on the urinary bladder in BCG treated patients.
Therefore, we propose to characterize in C57BL/6 mice,
bladder responses to intravesical BCG therapy. C57BL/6
mice were chosen not because of the Th1 biased response
of this strain [19], but because it will permit comparisons
with other animal models of bladder inflammation
already developed in C57BL/6 background [20,21].
In this first manuscript, we propose to determine whether
the intact mouse urinary bladder takes up BCG, the time-
dependent morphological alterations, and urinary
cytokine release in response to intravesical BCG. These
effects were compared to those elicited by other inflam-
matory stimuli (LPS and TNF-α) to differentiate BCG-spe-
cific effects from generalized inflammatory reactivity.
Results
BCG uptake by bladder urothelial cells
Twenty-four hours after instillation of BCG into the
mouse bladder, fast acid-positive bacteria were detected
within umbrella cells and underlying urothelial cells,
indicating that BCG is taken up by an apparent intact epi-
thelium (Figure 1A–C). The local inflammatory reaction
in response to BCG was characterized by an initial
increase in blood flow, enhanced vascular permeability
characterized by edema, and an influx of different effector
cells. At this time point, vasodilation was evident and
inflammatory cells (PMNs and lymphocytes) populated
the submucosal layer (Figure 1A). Interestingly, some
intraepithelial PMNs were also observed nearby urothelial
cells containing BCG (Figure 1C). PMNs invaded predom-
inantly the sub-urothelial mucosal layer (Figure 1A and
1E), and some inflammatory cells were also observed out-
side the urothelium, in the bladder lumen (Figure 1D).
In early time points, BCG induced an acute bladder
inflammation characterized by a strong vascular compo-
nent and edema. Characteristic photomicrographs of
BCG-induced bladder inflammation exemplify the trend
from an intense edema observed on days 1 and 7 (Figures
2A–B), and a gradual substitution of the edema by an
influx of PMNs and other inflammatory cells (Figure 2C–
F). Migrating inflammatory cells were initially observed in
submucosa (Figure 2A–B) and gradually invaded the
detrusor muscle (Figure 2C). From days 21 to 28, in addi-
tion to PMNs (Figure 2C–E), there was a substantial pres-
ence of monocyte-macrophages (Figure 3). During
chronic inflammation, several spots presented granu-
loma-like formations [22] (Figure 2C and 3).
All three stimuli induced bladder inflammation. BCG was
the strongest stimulus for PMN migration (Figure 4),
whereas edema appeared as an acute response to all stim-
uli (Figure 5). Interestingly, the area of edema formation
in response to BCG was biphasic, appearing as early as
twenty four hours after BCG instillation and declining at
fourteen days despite weekly instillations with BCG (Fig-
ure 5).
Table 1: Q-PCR PRIMERS
ACCESSION NUMBER SYMBOL FORWARD PRIMER REVERSE PRIMER
NM_009971 G-csf tgtcctcacaggaacgaagtc cttcctcctgcctcctctg
NM_009969 GM-csf gccacagttggaaggcagta aaatataatggtccctatcagtagaaa
NM_008337 IFNg agacttctgggcgtcctacc tgaccaagcctttcataagatg
NM_010548 IL-10 gctgagactttcgctcctctc agctccaaggcacctgttc
NM_008351 IL-12a attgccacggtttcctctc cctccttccctcctctgttc
NM_008352 IL-12b tcaccttctctgggcatttc gctattgggcatgcagtgag
NM_008361 IL-1b ttcccaatccctcaacagtc atgttctggagcaggcagtg
NM_008366 IL-2 acaatgtgggtgggtcactg tgtcaagatagccaggaagacac
NM_021283 IL-4 ggctttcctctttcccactc agccgccatgagagctaag
NM_031168 IL-6 gctgggattcttcaccactg tgacttgtcctgagacctgatg
NM_008176 KC (Cxcl1) tcgtctttcatattgtatggtcaac cgagacgagaccaggagaaac
NM_011337 Mip1a (Ccl3) ctccctcccagttggtcac ttaaagggcatatttattacttctctg
NM_013653 Rantes (Ccl5) cctattatgagccggcagag gggtgccgtagatcattctg
NM_013693 TNFa tcaggttgcctctgtctcag gctctgtgaggaaggctgtg
NM_010552 IL17a tcatttcctcctggcttttg tgagcttcccagatcacaga
NM_019508 IL17b ctttccccactctcccagac caaccaacccaacgccttac
NM_145837 IL17d ggccaaaacacacacaggta ccttggtcagaaccgtagga
NM_080729 IL17e gagtgggggtctcagctaca gatggggctctgtaacctttc
NM_145856 IL17f acttcagaggcgaaggcata tgactgtgcatgttggattt
NM_008359 IL17ra tttcatctttccagcctcct ggagcccagttgtctgtgag
NM_134437 IL17rd cagaagcgttggtagcagaa ccactgagacagcaccagaaPage 4 of 18
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response to BCG was maintained. For this purpose, mice
that received weekly instillations of BCG for 4 weeks had
the treatment discontinued (day zero), and were exam-
ined weekly up to 5 weeks for the presence of bladder
inflammation. The degree of inflammation observed at
the end of 4 weekly BCG instillations (day zero) was
maintained up to three weeks following discontinuation
of the therapy. Both the edema and PMNs were reduced at
4 weeks whereas the vasodilation was maintained for the
whole 5 weeks of observation (data not shown).
Together, these results indicate that bladder instillation
with BCG or TNF-α induce a classical inflammatory
response, as previously described for LPS [23,24]. How-
ever, relative to LPS and TNF-α, bladder responses to BCG
produce a higher PMN influx, with cells remaining well
after discontinuation of the treatment. Additionally, BCG
was the only agent capable of inducing formation of gran-
uloma-like structures.
Urinary cytokine levels
All three stimuli induced a time-dependent increase in
urinary cytokine levels (Figures 6, 7, 8, 9, and 10). Overall,
BCG induced the most comprehensive cytokine
responses, followed by LPS and TNF-α. Additionally,
some cytokine levels were altered acutely, whereas others
were elevated only after chronic stimulation (detailed
below). Cytokine induction relative to baseline levels was
calculated and ranked for each inflammatory agent (Table
2). Consistent with the rapid and massive neutrophil
infiltrates observed histologically, relative induction of
KC was highest in response to BCG, reaching 47,000 times
the control level. In addition to KC, BCG induced the
release of: MIP-1α, IL-1α, RANTES, IL-6, G-CSF, IL-1β, IL-
17, IL-4, IL-12(p70), and GM-CSF. In contrast to BCG, the
unique cytokine induced by LPS was IL-1β, and MIP-1α
reached the highest peak in response to acute LPS (Table
2). In addition to MIP-1α, LPS induced the release of the
following cytokines (listed in order of induction levels):
IL-1α, G-CSF, KC, IL-1β, IFNγ, RANTES, IL-4, IL-5, IL-12
(p70), TNFα, IL-17, and IL-10. Finally, G-CSF was found
Granuloma-like formation is indicated by wavy white linesFigure 3
Granuloma-like formation is indicated by wavy white lines. 
The presence of monocyte/macrophages was determined by 
IHC immunohistochemistry with rat anti-mouse macrophage 
monocyte antibody and secondary antibody anti-mouse Fab-
HRP (G).
DAY 28
Table 2: Peak urinary cytokine levels in response to BCG, TNF, and LPS calculated as percent of baseline
BCG TNF LPS
KC 47474 G-CSF 2424 MIP-1a 732446
MIP-1a 7314 KC 2305 IL-1a 10048
IL-1a 6422 IL-1a 1210 G-CSF 5045
RANTES 4732 IL-6 729 KC 4186
IL-6 4591 IL-2 410 Il-1b 1064
G-CSF 2244 IL-17 334 IFN-g 902
Il-1b 2236 MIP-1a 251 RANTES 751
IL-17 1469 Il-5 226 IL-4 716
IL-4 991 RANTES 226 Il-5 446
IL-12(p70) 540 IL-4 214 IL-12(p70) 393
GM-CSF 533 IFN-g 186 TNF-a 387
IFN-g 485 Il-1b 120 IL-17 387
Il-5 473 IL-12(p70) 119 IL-10 345
IL-2 410 GM-CSF 118 IL-2 255
IL-3 382 TNF-a 118 IL-12(p40) 248
TNF-a 349 IL-3 115 GM-CSF 235
IL-12(p40) 338 IL-12(p40) 111 IL-3 206
IL-10 235 IL-10 106 IL-6 173Page 5 of 18
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tion to G-CSF, TNF-α induced the following cytokines
(listed in order of induction levels): KC, IL-1α, IL-6, IL-2,
IL-17, MIP-1α, IL-5, RANTES, IL-4, IFN-γ, and IL-1β
(Table 2).
Both pro-inflammatory and anti-inflammatory cytokines
were detected in the mouse urine following inflammation
induced by BCG, TNF-α, and LPS. However, IL-17 was
induced primarily in response to BCG (Figure 9). In addi-
tion, we confirmed previous reports indicating that cer-
tain cytokines, such as IL-12 represented the early
responses of the urinary bladder to BCG [25]. In the
present study, this cytokine was the first to be released and
may reflect a direct stimulation of bladder resident cells,
whereas cytokines induced subsequent to this acute-
response phase may be the result of secondary mediator
synthesis by migrating inflammatory cells. In addition to
IL-12, other cytokines, like GM-CSF and IL-2, represent an
early response to all three agents.
To better characterize BCG-specific responses, the time-
courses of cytokine levels were mathematically modeled,
and time-dependent inductions of the 3 agents compared.
The time-course of IL-1β, IL-2, IL-3, IL-4, IL-6, IL-10, IL-
12p70, IL-17, GM-CSF, KC, and RANTES induction dis-
criminate between the effects of BCG relative to the
inflammatory responses obtained with LPS and TNF-α
(Table 3).
Next, we used CHIP/Q-PCR to investigate whether acute
BCG (24 hours after a single instillation) and chronic
BCG (7 days after four weekly instillations) would also
alter cytokine gene expression in the whole mouse blad-
der. With the exception of IL-6, KC, and MIP1α, acute
BCG instillation induced an increased expression of all
other cytokine and chemokine genes tested (Figures 11
and 12). Chronic BCG instillation induced increased
expression of all cytokine genes measured with the excep-
tion of IL-6 (Figures 11 and 12). In addition, particular
attention was paid to the IL-17 gene family since IL-17A
protein was one of the cytokines that discriminated
between BCG and the other pro-inflammatory stimuli
(Table 3). CHIP/Q-PCR results indicate a differential up
regulation of this family between acute and chronic BCG
(Figure 13).
Discussion
BCG uptake by bladder urothelial cells
Our results indicate that BCG is taken up by an apparent
intact urothelium and accumulates within urothelial cells.
Others have shown that E. coli is present in pod-like
PMNS. Mouse bladder morphological analysis in response to weekly instillations of BCG, LPS, and TNF-αFigure 4
PMNS. Mouse bladder morphological analysis in 
response to weekly instillations of BCG, LPS, and 
TNF-α. The time-course of inflammation was characterized 
by the number of polymorphonuclear leukocytes [PMNs] 
infiltrating the urinary bladder.
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Table 3: Discriminators of BCG effects versus TNF and LPS over time. 
Analyte p value
GM-CSF 0.001
IL-1 beta 0.007
IL-2 0.006
IL-3 0.032
IL-4 0.016
IL-6 0.000
IL-10 0.001
IL-12p70 0.012
IL-17 0.002
KC 0.018
RANTES* 0.001
Urinary cytokines response over time was determined using a mixed modeling approach, according to the following equation: Cytokine Level = (a) 
* Time + (b) Trx * Time, where Trx is BCG vs LPS & TNF-Alpha. A variance component covariance matrix was used to account for the correlation 
structure inherent in longitudinal measurements of cytokines.*Time squared interaction.Page 6 of 18
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a reservoir for bacteria and explains the persistence of
bladder infections [26]. It remains to be determined
whether this mechanism applies to BCG. Nevertheless,
the intact mouse urothelium is highly BCG responsive
and, as such, is a useful model to study mechanisms and
receptors that modulate the BCG uptake by the urinary
bladder. In this context, previous results from our labora-
tory indicate that LPS-fluorescein is taken up by the intact
mouse bladder urothelium, provokes bladder inflamma-
tion, and it is systemically distributed [23]. Together, our
findings indicate that although the urothelium present a
tightly controlled permeability, certain bacteria and toxins
find their way to penetrate this layer and to cause inflam-
mation.
Morphological alterations – PMNs infiltration
Our results indicate that bladder inflammation is part of
the response to intravesical BCG therapy (Figures 1, 2, 3).
This inflammation is characterized by a rapid onset of
edema and a graded and massive migration of inflamma-
tory cells (lymphocytes, PMNs and monocytes/macro-
phages) initially into the lamina propria, which spreads to
detrusor muscle as well (Figure 1). In humans, intravesical
therapy induces a well-described T-lymphocyte predomi-
nant inflammatory infiltrate in the bladder wall [27,28],
and it is proposed that helper and cytotoxic T cells and,
most probably, natural killer cells are necessary for anti-
tumor effects and the Th-1 biased immune response that
underlines BCG therapy [29]. Although BCG-treated
mouse bladder also exhibited lymphocytic infiltrates dur-
ing the acute response and macrophages during the late
phase responses (Figure 3), PMNs were overwhelmingly
present, suggesting the initial response is dominated by
these cells. Indeed, our histological results (Figure 1) and
the consequent morphological analysis (Figure 4) suggest
that PMNs are of prime importance in the model under
investigation. This cell-type is a bona fide inflammatory
cell, and it accounts for more than 90% of the urinary cel-
lular infiltrate early after BCG-mediated immune
responses. Indeed, Siracusano et al confirmed that in
humans, following intravesical BCG prophylaxis, a large
number of PMNs transmigrated through the urothelium
and are found isolated or adherent to detached urothelial
cells in the urine [30]. In addition, flow cytometry analysis
of fresh urine from patients receiving intravesical BCG
revealed TRAIL-expressing neutrophils [17]. Others have
shown in mice that PMNs migrate into the bladder after
intravesical BCG instillation, and that depletion of PMNs
from tumor-bearing mice completely abrogated antitu-
mor efficacy of BCG [31]. In vivo, depletion of PMNs
from BCG-treated mice significantly impaired CD4(+) T-
cell trafficking to the bladder [31]. Furthermore, PMNs
isolated from the urine of BCG-treated patients were a
major source of IL-8, growth-related oncogene-alpha,
MIP-1α, and inflammatory cytokine migration inhibitory
factor [31]. Therefore, our results agree with other find-
ings indicating that PMNs direct the migration of effector
cells to the bladder and are indispensable for effective
tumor immunotherapy [17,30,31].
Subsequent to the initial response, macrophages localized
in close proximity to neutrophils in a granuloma-like
structure that occurred in the mouse bladder over time
(Figure 3). The granuloma is a hallmark of Mycobacte-
rium-induced pathology [22,32,33]. BCG-induced granu-
loma seems to depend on TNF-α release [34,35]. Indeed,
transgenic mice expressing high serum levels of sTNFR1,
capable of neutralizing all circulating TNF, failed to
develop differentiated granulomas and bactericidal mech-
anisms, and succumbed to BCG infection [36]. However,
in our studies, chronic bladder instillation with TNF-α
alone was not enough to induce granuloma formation.
The latter could be due to a reduced uptake of TNF-α by
the urinary bladder, or that other factors are necessary for
the development of granuloma. Indeed, recent results
indicate that granuloma formation depends primarily on
the presence of transmembrane TNF-α [35].
Although systemic reactions (evolution of cellular
immune response or systemic production of cytokines
and oxygen free radicals) have been reported in response
to bladder instillation with BCG, a likely scenario is that
exposure to BCG results in a massive local inflammatory
response [37]. Correspondingly, in the present mouse
model, BCG induces a stronger PMN infiltration than
Edema. Mouse bladder morphological analysis in response to weekly instillations of BCG, LPS, and TNF-αFigure 5
Edema. Mouse bladder morphological analysis in 
response to weekly instillations of BCG, LPS, and 
TNF-α. The time-course of inflammation was characterized 
by the edema in the urinary bladder.
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Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of female miceFigure 6
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of 
female mice. Cytokine measurements were performed using fifty microliters of each sample and done in duplicate on the 
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-F11181, BioRad). 
The concentrations of analytes in these assays were quantitated using a standard curve. A regression analysis was performed to 
derive an equation that was then used to predict the concentration of the unknown samples. Time zero indicates basal levels of 
cytokines before instillation of any agent. A break at day 1 was added to each graph to contrast the altered cytokine levels 
when compared to basal levels. 
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Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of female miceFigure 7
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of 
female mice. Cytokine measurements were performed using fifty microliters of each sample and done in duplicate on the 
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-F11181, BioRad). 
The concentrations of analytes in these assays were quantitated using a standard curve. A regression analysis was performed to 
derive an equation that was then used to predict the concentration of the unknown samples. Time zero indicates basal levels of 
cytokines before instillation of any agent. A break at day 1 was added to each graph to contrast the altered cytokine levels 
when compared to basal levels. 
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Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of female miceFigure 8
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of 
female mice. Cytokine measurements were performed using fifty microliters of each sample and done in duplicate on the 
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-F11181, BioRad). 
The concentrations of analytes in these assays were quantitated using a standard curve. A regression analysis was performed to 
derive an equation that was then used to predict the concentration of the unknown samples. Time zero indicates basal levels of 
cytokines before instillation of any agent. A break at day 1 was added to each graph to contrast the altered cytokine levels 
when compared to basal levels. 
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Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of female miceFigure 9
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of 
female mice. Cytokine measurements were performed using fifty microliters of each sample and done in duplicate on the 
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-F11181, BioRad). 
The concentrations of analytes in these assays were quantitated using a standard curve. A regression analysis was performed to 
derive an equation that was then used to predict the concentration of the unknown samples. Time zero indicates basal levels of 
cytokines before instillation of any agent. A break at day 1 was added to each graph to contrast the altered cytokine levels 
when compared to basal levels. 
BMC Immunology 2007, 8:6 http://www.biomedcentral.com/1471-2172/8/6TNF-α and LPS. Additionally, granuloma formation was
only observed in response to chronic BCG instillation.
LPS and TNF as pro-inflammatory stimuli
The rationale for the use of LPS was that the bladder
inflammatory responses to this bacterial toxin have been
well characterized in our laboratory. We have presented
evidence that LPS induces a time-dependent cystitis [24]
concomitantly with the release of cytokines [23]. In con-
trast, although there is strong circumstantial evidence
indicating that TNF-α plays a fundamental role in bladder
inflammation [21], to our knowledge, the present study is
the first to use intravesical TNF-α as a model for cystitis.
TNF-α, at the concentration used in this study, was the
weakest inducer of cytokine release (Figures 6, 7, 8, 9, 10).
Although the concentration of TNF-α employed in this
study was at least 100-fold higher than the one used to
provoke neutrophil migration in the mouse skin [38], it is
possible that much higher concentrations of TNF-α would
lead to levels of urinary cytokines comparable to LPS. In
the context of TNF-α, it seems that the regimen applied in
this study, allowing at least 7 days between bladder instil-
lation and urine collection, decreased the possible bias of
TNF-α instillation on its urinary levels.
BCG-induced cytokine release
Keratinocyte-derived chemokine (KC; CXCl1; or Gro-α)
levels were the most altered by BCG (Table 2). As the
mouse does not produce IL-8, measurement of mouse KC,
a functional homolog of human IL-8 [18], could give us
some information regarding a role of this pro-inflamma-
tory cytokine in mediating BCG responses. KC is a potent
neutrophil chemoattractant that can be secreted by neu-
trophils, epithelial cells, endothelial cells, smooth muscle
cells, fibroblasts, macrophages, platelets, and lym-
phocytes [39]. The main stimuli for KC production are IL-
1, TNF-α, bacterial products, radical oxygen species, and
LPS, as well as the T cell products, such as IL-4 and IFN-γ
[39].
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of female miceFigure 10
Urinary cytokine levels (pg/ml) in response to weekly instillations of BCG, TNF-α, and LPS into the bladder of 
female mice. Cytokine measurements were performed using fifty microliters of each sample and done in duplicate on the 
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-F11181, BioRad). 
The concentrations of analytes in these assays were quantitated using a standard curve. A regression analysis was performed to 
derive an equation that was then used to predict the concentration of the unknown samples. Time zero indicates basal levels of 
cytokines before instillation of any agent. A break at day 1 was added to each graph to contrast the altered cytokine levels 
when compared to basal levels. Page 12 of 18
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altered by long term treatment with LPS or TNF-α. IL-17
belongs to a family of pro-inflammatory cytokines
[40,41]. IL-17 is a CD4 T cell-derived pro-inflammatory
and pro-angiogenic cytokine that further promotes IL-6
production and VEGF-mediated angiogenesis [42]. IL-17
is also involved in Fas ligand-induced inflammation [43].
Among the members of this family, IL-17A is the most
studied, and it is secreted by activated T cells and acts on
stromal cells to produce pro-inflammatory cytokines,
such as GM-CSF, G-CSF, CXCL1, and CXCL8 (IL-8) [44].
IL-17 is a strong activator of neutrophil migration and
infiltration, although perhaps not directly [44,45]. To our
knowledge, this is the first report of an increase in urinary
IL-17 release and gene expression in response to intravesi-
cal BCG.
These findings suggest that the therapeutic effects of BCG
are due in part to the rapid accumulation of antigen pre-
senting, and activated immune cells that are responsible
for the production of a multiphasic immune response as
demonstrated by the presence of TH1 (IFN-γ, IL-1, IL-12,
and TNF-α), TH2 (IL-4, IL-5, IL-6, and IL-10), and TH17
(IL-17 and IL-6) cytokines.
Time-course of cytokine release
Because of the innumerous side-effects of BCG therapy,
other authors have determined the effect of different prep-
arations [46] and regimens of intravesical BCG instilla-
tions in mice on the dynamics of Th1/Th2 cytokines
[19,47]. It was suggested that the first BCG instillation is
fundamental for the overall response [19]. In the present
study, cytokine levels in the urine were elevated as early as
1 day after BCG instillation. The earliest cytokines
induced by BCG included: IL-12 (p70 and p40), IL-2, IL-
3, IL-4, MIP-1α, IL-10, and KC (Figures 6, 7, 8, 9, 10).
Those cytokines were released when inflammatory cell
infiltrates were minimal (Figure 2A–B), and may reflect a
direct effect of BCG on resident cells, such as urothelial
cells and fibroblasts. Indeed, BCG stimulates IL-12 release
by human urothelial cells in culture concomitantly with
up regulation of toll-like receptors -2 and -4 [15]. Of inter-
est, O'Donnel and collaborators have shown that IL-12
expression preceded the other cytokines [25]. In the
present work, IFN-γ, a major Th1 cytokine, appeared in
the urine late in response to BCG (Figures 6, 7, 8, 9, 10).
In humans, IFN-γ was barely detectable after the first two
BCG instillations, but gradually increased from the third
instillation onwards [48]. The peak weekly cytokine
response per patient usually occurred between the fourth
and sixth treatment for IFN-γ [49]. Others have found
IFN-γ to be a late cytokine in response to BCG, and its
induction requires involvement of various endogenously
produced Th1 and Th2 cytokines.
Among the cytokines released by BCG, attention has been
paid to IL-6 because its urinary levels are correlated with
symptom scores in cystitis [50,51] and are reduced by
BCG therapy in bladder cancer [52]. However, our CHIP/
Q-PCR results did not demonstrate a significant increase
in IL-6 gene following acute and chronic BCG.
Regarding the anti-inflammatory cytokines, we found that
BCG also induces the release of IL-10 as early as 1 day after
the first instillation. Others have found that BCG also
releases IL-10 from the mouse bladder [37]. IL-10 is an
important down-regulator of delayed-type hypersensitiv-
Chromatin immunoprecipitation (CHIP)/quantitative real-time polymerase chain reaction (Q-PCR)-B sed AssaysFigure 11
Chromatin immunoprecipitation (CHIP)/quantita-
tive real-time polymerase chain reaction (Q-PCR)-
Based Assays. Female C57BL/6J mice were anesthetized 
and instilled with 200 μl of one of the following substances: 
BCG (TheraCys®-Aventis-Pasteur; total dose of 1.35 mg) or 
pyrogen-free saline on days 1, 7, 14, and 21, as described in 
methods. Mice were euthanized 24 hours after a single instil-
lation (BCG Acute) or 7 days after 4 weekly instillations 
(BCG Chronic). A total of 60 mice were used (20 mice per 
group). Bladders were removed rapidly, frozen, and shipped 
to Genpathway http://www.genpathway.com/ for querying 
the chromatin for transcription of listed genes (Genpath-
way's TranscriptionPath Query assay). After isolation, the 
chromatin was incubated with an antibody against RNA 
polymerase II (Abcam) to precipitate the DNA transcrip-
tome. The final CHIP DNAs were then used as templates in 
Q-PCR reactions using specific primer pairs (Table Table 1). 
Results are presented as average and standard error of Tran-
scription Events Detected Per 1000 Cells. Results were 
grouped to facilitate their visualization. Cytokines. Graphics 
illustrated in figures 11, 12, and 13 present the same X-axis 
to permit comparisons between gene families.
IFN-g IL-10 IL-12a IL-12b IL-1b IL-2 IL-4 IL-6 TNF
0
4
8
12
16
20
24
T
ra
n
s
c
ri
p
ti
o
n
 E
v
e
n
ts
 D
e
te
c
te
d
 /
 1
0
0
0
 c
e
lls
*
*
*
*
*
**
*
*
*
**
*
*
*
*
Genes
 Saline
 BCG Acute
 BCG Chronic Page 13 of 18
(page number not for citation purposes)
BMC Immunology 2007, 8:6 http://www.biomedcentral.com/1471-2172/8/6ity (DTH). In addition, in mouse studies, the absence of
IL-10 abrogated either by antibody inhibition or the use
of genetically modified, IL-10 deficient mice, resulted in
enhanced DTH responses [37].
Together, our results demonstrate a tractable approach for
assessing the complex cytokine networks induced by BCG
during both acute and chronic stages. This approach also
provided the means to make relatively rigorous compari-
sons of the BCG response to other pro-inflammatory stim-
uli. Our analysis revealed that IL-1β, IL-2, IL-3, IL-4, IL-6,
IL-10,IL-17, GM-CSF, KC, and Rantes were the best dis-
criminators of the BCG response relative to TNF-α and
LPS. Although the levels of IL-2 and IL-4 at a given time
point were relatively low, our mathematical model takes
into consideration the cytokines over time rather than
their individual values. Using this approach, both IL-2
and IL-4 were included as discriminators for the BCG
responses because of their significant p values (Table 3).
We went further to determine whether acute and chronic
BCG treatment could alter bladder gene expression. For
this purpose, we examined 2 groups of mice that received
BCG intravesicaly, as described in methods. The acute
group was examined 24 hours after a single instillation
and a chronic group was examined 7 days after 4 weekly
instillations. We used a combination of CHIP assay and
Chromatin immunoprecipitation (CHIP)/quantitative real-time polymerase chain reaction (Q-PCR)-B sed AssaysFigure 13
Chromatin immunoprecipitation (CHIP)/quantita-
tive real-time polymerase chain reaction (Q-PCR)-
Based Assays. Female C57BL/6J mice were anesthetized 
and instilled with 200 μl of one of the following substances: 
BCG (TheraCys®-Aventis-Pasteur; total dose of 1.35 mg) or 
pyrogen-free saline on days 1, 7, 14, and 21, as described in 
methods. Mice were euthanized 24 hours after a single instil-
lation (BCG Acute) or 7 days after 4 weekly instillations 
(BCG Chronic). A total of 60 mice were used (20 mice per 
group). Bladders were removed rapidly, frozen, and shipped 
to Genpathway http://www.genpathway.com/ for querying 
the chromatin for transcription of listed genes (Genpath-
way's TranscriptionPath Query assay). After isolation, the 
chromatin was incubated with an antibody against RNA 
polymerase II (Abcam) to precipitate the DNA transcrip-
tome. The final CHIP DNAs were then used as templates in 
Q-PCR reactions using specific primer pairs (Table 1). 
Results are presented as average and standard error of Tran-
scription Events Detected Per 1000 Cells. Results were 
grouped to facilitate their visualization. IL-17 family. Graphics 
illustrated in figures 11, 12, and 13 present the same X-axis 
to permit comparisons between gene families.
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Chromatin immunoprecipitation (CHIP)/quantitative real-time polymerase chain reaction (Q-PCR)-B sed AssaysFigure 12
Chromatin immunoprecipitation (CHIP)/quantita-
tive real-time polymerase chain reaction (Q-PCR)-
Based Assays. Female C57BL/6J mice were anesthetized 
and instilled with 200 μl of one of the following substances: 
BCG (TheraCys®-Aventis-Pasteur; total dose of 1.35 mg) or 
pyrogen-free saline on days 1, 7, 14, and 21, as described in 
methods. Mice were euthanized 24 hours after a single instil-
lation (BCG Acute) or 7 days after 4 weekly instillations 
(BCG Chronic). A total of 60 mice were used (20 mice per 
group). Bladders were removed rapidly, frozen, and shipped 
to Genpathway http://www.genpathway.com/ for querying 
the chromatin for transcription of listed genes (Genpath-
way's TranscriptionPath Query assay). After isolation, the 
chromatin was incubated with an antibody against RNA 
polymerase II (Abcam) to precipitate the DNA transcrip-
tome. The final CHIP DNAs were then used as templates in 
Q-PCR reactions using specific primer pairs (Table 1). 
Results are presented as average and standard error of Tran-
scription Events Detected Per 1000 Cells. Results were 
grouped to facilitate their visualization. Chemokines. Graph-
ics illustrated in figures 11, 12, and 13 present the same X-
axis to permit comparisons between gene families.
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method to assess genes of interest in the bladder transcrip-
tome. This assay takes into consideration genes that are
actively transcribed in contrast to cDNA array technolo-
gies that queries RNA accumulation. The results obtained
in the acute group (24 hours following a single BCG instil-
lation) indicate that with the exception of IL-6, KC, and
MIP1α, there was a significant increase in all other RNA
encoding cytokines and chemokines. In contrast, the RNA
accumulation in consequence to chronic BCG instillation
had a strong correlation with the levels of cytokines and
chemokines and the increased urinary levels of these pro-
teins. The disadvantage of the CHIP/Q-PCR method is the
amount of chromatin necessary for CHIP, which limits
this analysis to the whole bladder and not the specific lay-
ers. Our CHIP/Q-PCR results have to be taken in the con-
text that migrating inflammatory cells, in addition to
resident cells, contributed to the measured values. Future
studies using individual bladder layers such as the urothe-
lium, submucosa, and detrusor muscle should provide
further detail on the source of urinary cytokines.
Conclusion
BCG induces a unique type of persisting bladder inflam-
mation different from TNF-α, LPS, and, most likely other
classical pro-inflammatory stimuli. Among the different
cytokines, this study highlighted the importance of IL-1β,
IL-2, IL-3, IL-4, IL-6, IL-10, IL-17, GM-CSF, KC, and Rantes
as discriminators between overall inflammation and blad-
der responses to BCG instillation. To the best of our
knowledge, the present work is the first to report that BCG
induces an increase in the IL-17 family genes.
Materials and methods
Animals
Ten to twelve week-old C57BL/6 female mice (The Jack-
son Laboratory; Bar Harbor, ME) were anesthetized,
transurethrally catheterized as previously described
[21,24,53,54], and instilled with 200 μl of one of the fol-
lowing substances: BCG (TheraCys®-Aventis-Pasteur; total
dose of 1.35 mg [19]), E. coli LPS (strain 055:B5; 100 μg/
ml [23,24,55]), TNFα (1 μg/ml), or pyrogen-free saline on
days 1, 7, 14, and 21.
The urine was collected for cytokine analysis at time
points indicated below (n = 6 mice per group), and the
urinary bladder was removed for morphometric analysis
(n = 8). All animal experimentation described here was
performed in conformity with the "Guiding Principles for
Research Involving Animals and Human Beings"
(OUHSC Animal Care & Use Committee protocols #05-
088 and 05-081).
Histological Analyses
Bladders were fixed in 4% buffered formaldehyde,
embedded in paraffin, cut serially into four 5-μm sections
(8 μm apart), and subsequently stained with hematoxylin
and eosin (H&E) and Ziehl-Neelsen (acid fast) [36]. Mac-
rophages were visualized using immunohistochemistry
with rat anti-mouse macrophage monocyte antibody
(MCA519G, Serotec LTD, Oxford, UK) and secondary
antibody anti-mouse Fab-HRP, as previously described
[24]. Bladder stained sections were visualized under
microscope (Eclipse E600, Nikon, Lewisville, TX). All tis-
sues were photographed at room temperature by a digital
camera (DXM1200; Nikon). Exposure times were held
constant when acquiring images from different groups.
Morphometric analysis of inflammation
Images were analyzed with Image-Pro Analyzer® (Media
Cybernetics Inc.; Silver Spring, MD). The number of poly-
morphonuclear [PMNs] leukocytes was the most repro-
ducible sign of acute bladder inflammation and,
therefore, it was used for quantification. PMNs were
counted in a blinded fashion in 5 random fields per slide
in two non-consecutive sections per urinary bladder at
200× magnification. The number of PMNS was normal-
ized per cross-sectional area (μm2). In addition, the area
of edema was determined from the same cross sections
and normalized per cross-sectional area of the mucosa/
submucosa.
Urine collection
Urine for cytokine analysis was collected during early
morning hours at the following time points: time 0 (pre-
vious to first instillation to determine basal release), one
and seven days after a single bladder instillation, and
seven days after each subsequent intravesical instillation
performed at days 7, 14, and 21. A sample of urine from
each mouse was transferred to a test tube and stabilized by
the addition of an equal volume of a 10-fold concentrated
buffer containing 2 M Tris-HCl (pH 7.6), 5% BSA, 0.1%
sodium azide, and the following protease inhibitors:
aprotinin, pepstatin, leupeptin at 0.01 mg/ml, and AEBSF,
4-(2-aminoethyl) benzenesulfonyl fluoride at 0.1 mg/ml,
as described by O'Donnell et al [25]. Samples were then
stored at -70C for batch cytokine analysis.
Urinary Cytokines
Buffered urine samples were thawed and fifty microliters
of each sample were analyzed in duplicate on the
Luminex 100 (Bio-Rad Laboratories, Hercules, CA) using
a Bio-Plex Mouse Cytokine 18-Plex (catalog #171-
F11181, BioRad). The Bio-Plex suspension array system,
which incorporates a novel technology using color-coded
microspheres, permits the simultaneous detection of 18
cytokines and chemokines in a single well of a 96-well
microplate. Cytokines measured included interleukin-1βPage 15 of 18
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BMC Immunology 2007, 8:6 http://www.biomedcentral.com/1471-2172/8/6(IL-1β), IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12
(p40), IL-12 (p70), IL-17, granulocyte colony factor (G-
CSF), granulocyte macrophage colony stimulating factor
(GM-CSF), interferon-γ (IFN-γ), tumor necrosis factor-
α(TNF-α), keratinocyte-derived chemokine (KC), CCL3
[macrophage inflammatory protein-1α (MIP-1α)], and
CCL5 [regulated upon activation, normal T cell expressed
and secreted (RANTES)]. A broad sensitivity range of
standards (Biosource International, Camarillo, CA) rang-
ing from 1.95 to 32000 pg/ml were used to help enable
the quantitation of a dynamic wide range of cytokine con-
centrations, and to provide the greatest sensitivity. The
concentrations of analytes in these assays were quanti-
tated using a standard curve. A 4 parameter logistic regres-
sion was performed to derive an equation that was then
used to predict the concentration of the unknown sam-
ples.
Chromatin immunoprecipitation (CHIP) quantitative real-
time polymerase chain reaction (Q-PCR)-Based Assays
To determine whether intravesical BCG treatment would
alter bladder cytokine gene expression, we used chroma-
tin immunoprecipitation combined with Q-PCR. For this
purpose, female C57BL/6J mice were anesthetized and
instilled with 200 μl of one of the following substances:
BCG (TheraCys®-Aventis-Pasteur; total dose of 1.35 mg)
or pyrogen-free saline on days 1, 7, 14, and 21, as
described above. Mice were euthanized with pentobarbi-
tal (200 mg/kg, i.p.) 24 hours after a single instillation
(BCG acute) or 7 days after 4 weekly instillations (BCG
chronic). A total of 60 mice were used (20 mice per
group). Bladders were removed rapidly, frozen, and were
shipped to Genpathway [56] for querying the chromatin
for gene transcription (Genpathway's TranscriptionPath
Query assay) [57].
The urinary bladders were exposed briefly to formalde-
hyde for cross-linking of the proteins and DNA together,
followed by sonication to fragment the DNA into pieces
of approximately 300–500 base pairs. An antibody
against RNA polymerase II (Abcam) was then used to pre-
cipitate the DNA transcriptome. The Ab-protein-DNA
complexes were purified using beads coupled to protein
A. The DNA was isolated from the complexes using a com-
bination of heat to reverse cross-linking, RNase and pro-
teases, and then purified using phenol extraction and
EtOH precipitation. The final CHIP DNAs were then used
as templates in quantitative PCR reactions using primer
pairs specific for each gene of interest. Quantitative PCR
was carried out using Taq polymerase (iQ SYBR Green
Supermix, Bio-Rad). Primer pairs were designed using
Primer 3 [58]. Details of the primer sequences are given in
Table 1. The designed primers shared 100% homology
with the target sequence but no significant homology with
other sequences.
Q-PCRs were run in triplicate and the values were trans-
ferred into copy numbers of DNA using a standard curve
of genomic DNA with known copy numbers. The result-
ing transcription values for each gene were also normal-
ized for primer pair amplification efficiency using the Q-
PCR values obtained with Input DNA (unprecipitated
genomic DNA). Results are presented as Transcription
Events Detected Per 1000 Cells for each gene tested.
Statistical Analysis
Morphometric analysis
We did not assume equal variance because the variance of
PMN population is unknown; p values were calculated
using a Welch's test (GraphPad Prism software version
4.0; GraphPad Software, Inc. San Diego, CA). A nominal
p value less than 0.05 was considered statistically signifi-
cant.
Q-PCR
The difference between two mean values was analyzed
with an unpaired Student's t-test (GraphPad Prism soft-
ware version 4.0; GraphPad Software, Inc. San Diego,
CA). A nominal p value less than 0.05 was considered sta-
tistically significant.
Urinary Cytokines
The small sample sizes at each time point precluded the
use of standard analysis methods such as t-tests compar-
ing baseline to time X. To gain statistical power, urinary
cytokine response over time was parameterized through a
"mixed model" [59] according to the following equation:
Cytokine Level = α * Time + β * Trx * Time
where α and β are beta coefficients, Trx is BCG vs LPS &
TNF-α, and Time is in days. If the Trx*Time interaction
was found to be significant a Trx*Time2 interaction was
tested. Only the p value from the highest order interaction
was reported. A variance component covariance matrix
was used to account for the correlation structure inherent
in the longitudinal measurements of cytokines. A cytokine
was considered to be statistically significant if the nomi-
nal interaction p value was less than 0.05. All mixed
model analysis was performed in the SAS system v 9.1.3
(Cary, NC).
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